Predict your next investment

Private Equity
emigrantcapital.com

See what CB Insights has to offer

Investments

15

Portfolio Exits

5

Funds

1

About Emigrant Capital

Emigrant Capital is a private investment firm that offers middle market companies the capital and resources they need to realize their full potential. Through its experience as a successful deal sponsor and the talents of its executive partners, Emigrant provides not only the optimal capital structure, but also a wealth of resources to help ensure success.

Emigrant Capital Headquarter Location

6 East 43rd Street

New York, New York, 10017-4624,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Emigrant Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Emigrant Capital in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Emigrant Capital News

Frequency Therapeutics Completes $42M Series B Financing

Jan 7, 2019

Frequency Therapeutics , a Woburn, Mass.-based clinical-stage biotechnology company creating a new class of drugs based on small molecule stimulation of dormant stem cells within the body which we refer to as Progenitor Cell Activation (PCA), closed a $42m Series B financing. The round, which brings the total capital raised by the company to $87m, was led by Taiwania Capital Management and Axil Capital, with participation from Yonjin Capital and DF Investments and existing investors Polaris Founders Capital, Alexandria Venture Investments, CoBro Ventures, Korea Investment Partners and Emigrant Capital. In connection with the financing, Joel Marcus, Executive Chairman and Founder of Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments, and Michael Huang, Managing Partner of Taiwania Capital Management, have joined Frequency’s Board of Directors. In addition, Fred Shane, a partner with Axil Capital and Daguang Wang Ph.D., Managing Director of Yonjin Capital, have joined the board as observers. The company intends to use the funds for the advancement of its clinical candidate, FX-322, for hearing regeneration, and for the continued expansion of its pipeline with new therapeutic applications from the PCA Regeneration platform. Le by David Lucchino, President and Chief Executive Officer, and Marc Cohen, Executive Chairman, Frequency leverages its Progenitor Cell Activation (PCA) Regeneration platform, which uses a combination of small molecules, to stimulate progenitor cells within the body to repair diseased or damaged tissue. This technology enables native tissue regeneration without modifying genes or removing cells from the body. Through the transitory activation of these cells, the company enables disease modification without the complexity of genetic engineering. FinSMEs 07/01/2018

Emigrant Capital Investments

15 Investments

Emigrant Capital has made 15 investments. Their latest investment was in Frequency Therapeutics as part of their Series B on January 1, 2019.

CBI Logo

Emigrant Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/7/2019

Series B

Frequency Therapeutics

$42M

No

3

4/11/2017

Series A

Frequency Therapeutics

$32M

Yes

4

10/11/2006

Unattributed VC

Lev Pharmaceuticals

$21M

Yes

9/21/2006

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

3/10/2006

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/7/2019

4/11/2017

10/11/2006

9/21/2006

3/10/2006

Round

Series B

Series A

Unattributed VC

Unattributed VC

Unattributed VC

Company

Frequency Therapeutics

Frequency Therapeutics

Lev Pharmaceuticals

Subscribe to see more

Subscribe to see more

Amount

$42M

$32M

$21M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

4

10

10

Emigrant Capital Portfolio Exits

5 Portfolio Exits

Emigrant Capital has 5 portfolio exits. Their latest portfolio exit was Frequency Therapeutics on October 03, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/3/2019

IPO

$991

2

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

10/3/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

IPO

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Emigrant Capital Acquisitions

3 Acquisitions

Emigrant Capital acquired 3 companies. Their latest acquisition was Forward Foods on September 06, 2006.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/6/2006

Acquired

8/15/2006

Subscribe to see more

$99M

Subscribe to see more

10

2/11/2000

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/6/2006

8/15/2006

2/11/2000

Investment Stage

Companies

Subscribe to see more

Subscribe to see more

Valuation

Total Funding

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Sources

10

10

Emigrant Capital Fund History

1 Fund History

Emigrant Capital has 1 fund, including Emigrant Capital.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/7/1999

Emigrant Capital

Diversified Private Equity

$150M

1

Closing Date

7/7/1999

Fund

Emigrant Capital

Fund Type

Diversified Private Equity

Status

Amount

$150M

Sources

1

Emigrant Capital Team

6 Team Members

Emigrant Capital has 6 team members, including current Chief Executive Officer, Howard Milstein.

Name

Work History

Title

Status

Howard Milstein

Chief Executive Officer

Current

Gilbert S. Stein

Chief Executive Officer, President

Current

Kenneth L. Walters

Senior Managing Director

Current

John G. Appel

Managing Director

Current

Lawrence Adolf

Managing Director

Former

Name

Howard Milstein

Gilbert S. Stein

Kenneth L. Walters

John G. Appel

Lawrence Adolf

Work History

Title

Chief Executive Officer

Chief Executive Officer, President

Senior Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.